Last updated: September 1, 2026
Clevidipine is a hospital-only, intravenous dihydropyridine calcium-channel blocker marketed in the U.S. as Cleviprex. Its commercial value comes from rapid, titratable blood-pressure control in perioperative and critical-care settings, rather than chronic outpatient use. The product has a narrow but defensible hospital niche, with competition from nicardipine, labetalol, esmolol and nitroprusside.
The financial trajectory has three stages: U.S. launch and adoption under The Medicines Company, portfolio monetization through the company’s 2016 sale of cardiovascular assets to Chiesi Farmaceutici, and post-exclusivity market exposure as generic clevidipine products enter or approach the market. Chiesi does not separately disclose current Cleviprex revenue, which limits product-level valuation.
What is clevidipine and how is it used?
Clevidipine butyrate is an ultrashort-acting, intravenously administered calcium-channel blocker. Cleviprex is supplied as a lipid emulsion at a concentration of 0.5 mg/mL.
The FDA-approved indications are:
- Reduction of blood pressure when oral therapy is not feasible or desirable
- Perioperative blood-pressure control
- Short-term treatment in acute-care and intensive-care environments
The product has a rapid onset and short duration, allowing clinicians to adjust the infusion frequently. The formulation is administered through a dedicated infusion system and requires handling controls associated with its lipid emulsion vehicle. The FDA label warns about lipid intake, contamination risk and contraindications in patients with allergies to soy or egg products or significant defects in lipid metabolism.[1]
Clevidipine is not a chronic maintenance medicine. Its commercial demand depends on surgical volume, intensive-care utilization, hospital protocols, formulary placement and emergency blood-pressure management.
What is the FDA regulatory status of clevidipine?
Cleviprex was approved by the FDA in 2008 under New Drug Application 022156.[1] The regulatory profile is summarized below.
| Attribute |
Clevidipine status |
| Active ingredient |
Clevidipine butyrate |
| Brand |
Cleviprex |
| Dosage form |
Intravenous injectable lipid emulsion |
| Strength |
0.5 mg/mL |
| FDA approval |
2008 |
| Primary use |
Short-term blood-pressure reduction |
| Main setting |
Hospitals, operating rooms and intensive-care units |
| Administration |
Continuous intravenous infusion |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Primary generic pathway |
ANDA under section 505(j) |
The product’s regulatory advantages are clinical familiarity, a defined perioperative indication and a formulation that supports fast titration. Its disadvantages are the need for intravenous administration, higher acquisition cost than many generic antihypertensive alternatives and hospital dependence.
What is the Orange Book status of Cleviprex?
Clevidipine is an approved small-molecule drug, so its principal generic-exclusivity issue is ANDA competition rather than biosimilar substitution. FDA Orange Book analysis should focus on listed patents, pediatric exclusivity, regulatory exclusivity and the presence of approved abbreviated applications.[2]
The commercial significance of Orange Book protection has changed over time:
- The original Cleviprex franchise benefited from the absence of approved generic alternatives during its early commercial period.
- Any remaining formulation or method-of-use patents have less practical value if generic applicants can design around them or if the listed patents have expired.
- Hospital products are vulnerable to rapid price erosion once an injectable generic is approved, particularly when multiple suppliers qualify for institutional contracts.
Publicly available company filings do not provide a current, standalone Cleviprex patent valuation. The relevant diligence question is whether any active U.S. patent claims cover the marketed emulsion, manufacturing process or approved use, and whether those claims are listed in the current Orange Book. FDA’s Orange Book remains the controlling source for listed patent and exclusivity information.[2]
When does clevidipine lose exclusivity?
Clevidipine’s core market protection is no longer comparable to that of a recently launched product. FDA approval occurred in 2008, and the five-year new chemical entity exclusivity period would have ended in 2013, subject to the specific regulatory history. Any pediatric extension or additional exclusivity would also have expired by the current period unless a later qualifying approval created a separate period.
The main commercial protection therefore shifted from statutory exclusivity to:
- Hospital formulary adoption
- Physician familiarity
- Reliable supply of sterile injectable product
- Manufacturing complexity
- Contracting relationships
- Clinical preference for rapid titration
The absence of a chronic outpatient market reduces the value of brand loyalty. Hospital pharmacy committees can substitute products when clinical protocols, supply and price support the change.
What patents protect clevidipine?
The original intellectual-property estate was directed at clevidipine compounds, pharmaceutical compositions, injectable emulsions and therapeutic use. The most commercially relevant claim categories are:
| Patent category |
Commercial purpose |
Generic vulnerability |
| Active compound claims |
Protect clevidipine or related chemical entities |
Usually expire earliest and are difficult to extend |
| Composition claims |
Protect the injectable emulsion and excipients |
Can be important if narrowly drafted |
| Formulation claims |
Protect stability, particle size, vehicle or concentration |
Subject to design-around risk |
| Method-of-use claims |
Protect intravenous blood-pressure control |
Limited if generic labeling can omit protected use |
| Manufacturing claims |
Protect production or sterilization processes |
May create supply barriers without blocking all ANDA entry |
The formulation has greater strategic relevance than the active ingredient alone because clevidipine is sold as a specialized injectable emulsion. Manufacturing sterile lipid emulsions at commercial scale can create technical barriers, but those barriers are not equivalent to patent exclusivity. A generic manufacturer can compete through an alternative process if it satisfies FDA quality requirements.
Have there been Paragraph IV challenges to Cleviprex?
Paragraph IV litigation is the principal U.S. pathway for challenging listed Orange Book patents before generic launch. The available public record does not establish a current, material Paragraph IV dispute that would preserve long-term branded exclusivity for Cleviprex.
The risk profile is more consistent with post-exclusivity injectable competition:
- An ANDA applicant may certify that listed patents have expired.
- An applicant may file a Paragraph IV certification against any remaining listed patent.
- A generic may omit a patented method of use through a section viii statement.
- Multiple ANDA approvals can accelerate hospital price competition.
The absence of a major current litigation event matters financially. There is no clear litigation-driven basis for assuming a delayed generic launch or a damages opportunity comparable to large outpatient products.
Which companies compete with clevidipine?
Clevidipine competes in the acute intravenous blood-pressure management market, not in the broad hypertension market.
| Product |
Active ingredient |
Typical competitive position |
| Cleviprex |
Clevidipine |
Rapid titration; perioperative and ICU use |
| Cardene IV |
Nicardipine |
Established hospital alternative; broad critical-care use |
| Labetalol injection |
Labetalol |
Lower-cost beta-blocker alternative |
| Esmolol injection |
Esmolol |
Useful where heart-rate control is also required |
| Nitropress |
Sodium nitroprusside |
Potent vasodilator with monitoring and toxicity considerations |
| Hydralazine injection |
Hydralazine |
Intermittent dosing rather than continuous titratable infusion |
Nicardipine is the closest branded and clinical competitor. Both products are titratable intravenous agents used in operating rooms, intensive-care units and acute neurologic settings. Clevidipine can benefit from rapid offset and a favorable titration profile, while nicardipine often benefits from broader institutional familiarity and generic availability.
How strong is the clevidipine patent estate?
The patent estate is commercially moderate to weak in the current period. The product has technical differentiation, but the original approval date places it well beyond the period when compound patents and five-year regulatory exclusivity would ordinarily protect the franchise.
The strongest remaining barriers are operational:
- Specialized sterile-emulsion manufacturing
- Validation of container and infusion compatibility
- Stability and preservative controls
- Hospital supply reliability
- Formulary and group-purchasing contracts
Those barriers can delay entry or limit the number of successful suppliers, but they do not create durable monopoly economics. Injectable manufacturing can also produce temporary shortages that improve branded pricing, although shortage-driven revenue is volatile and difficult to underwrite.
What licensing deal transferred Cleviprex to Chiesi?
Chiesi acquired The Medicines Company’s U.S. cardiovascular franchise in 2016. The transaction was reported at approximately $792 million and included Cleviprex and other cardiovascular assets.[3]
The transaction had two strategic consequences:
- The Medicines Company monetized a mature hospital franchise while concentrating on other pipeline and specialty assets.
- Chiesi obtained a commercial hospital product with established clinical use and relatively predictable demand, but with long-term exposure to generic competition.
The deal value should not be treated as the standalone value of Cleviprex. It covered a portfolio and associated commercial infrastructure. Chiesi’s later public reporting has generally grouped products within broader business segments rather than disclosing a separate Cleviprex revenue line.[4]
What is the financial trajectory of clevidipine?
Cleviprex generated meaningful pre-generic revenue for The Medicines Company, but its scale was modest relative to blockbuster outpatient drugs. The product’s revenue ceiling is constrained by:
- Hospital-only use
- Short treatment duration
- Protocol-based utilization
- Competition from low-cost injectable agents
- Limited ability to expand into chronic hypertension
- Dependence on surgical and ICU volumes
The financial trajectory can be divided into four periods.
| Period |
Financial pattern |
Main driver |
| 2008-2012 |
Commercial buildout |
Hospital adoption and clinical education |
| 2013-2015 |
Maturing branded franchise |
Formulary penetration and repeat institutional demand |
| 2016 |
Portfolio monetization |
Sale of cardiovascular assets to Chiesi |
| 2017 onward |
Mature-product economics |
Segment reporting, contracting and generic-entry risk |
The 2016 transaction confirms that Cleviprex had strategic value as a mature hospital product. It does not indicate that the brand had growth characteristics typical of a protected specialty medicine.
Current product-level revenue is not separately disclosed by Chiesi. As a result, the most defensible financial assessment is directional:
- Revenue is likely below the product’s peak branded value after generic availability.
- Gross-to-net pressure is likely higher in hospital accounts than in retail pharmacy.
- Price erosion depends on the number of approved suppliers and procurement contracts.
- Volume can remain stable even while revenue declines.
- Supply disruptions could temporarily support brand utilization but would not improve long-term exclusivity.
What generic entry risks exist for clevidipine?
Generic entry risk is high. Clevidipine is a small molecule with an established FDA-approved injectable presentation and a mature clinical market.
The principal risks are:
Price erosion
Hospitals commonly purchase injectable products through group purchasing organizations, wholesalers and direct contracts. A second supplier can pressure price, while three or more suppliers can materially change contracting economics.
Formulation complexity
The lipid emulsion creates higher technical requirements than a conventional aqueous injection. That may slow approval and reduce the initial supplier pool. It does not eliminate generic risk.
Limited switching costs
Clinical teams may prefer clevidipine in specific protocols, but hospitals can substitute nicardipine or other intravenous agents when price, supply or formulary policy changes.
Supply-chain competition
Sterile injectable shortages can create temporary openings for the branded product. These periods should not be modeled as permanent share recovery.
Labeling strategy
A generic applicant can use a Paragraph IV certification or a section viii carve-out depending on the listed patent claims. Method-of-use patents are less effective when the generic label excludes the protected indication and the remaining approved uses remain commercially viable.
What is the outlook for clevidipine revenue?
The base case is a mature, declining hospital franchise with residual value from brand recognition, supply reliability and clinical preference. Revenue growth would require one of four developments:
- Sustained growth in perioperative or ICU utilization
- A shortage affecting competing products
- Successful premium positioning against generic alternatives
- A narrower hospital segment where clinicians value clevidipine’s titration profile enough to preserve price
A high-growth scenario is difficult to support without a new indication, materially expanded use or renewed exclusivity. A downside scenario includes rapid multi-source generic entry, formulary exclusion and conversion to nicardipine or low-cost alternatives.
How does clevidipine compare with nicardipine?
Clevidipine has a shorter duration of action and is designed for fine dose adjustment. Nicardipine has broader market familiarity and a longer commercial history as a hospital intravenous antihypertensive.
| Factor |
Clevidipine |
Nicardipine |
| Titration |
Very rapid |
Rapid |
| Formulation |
Lipid emulsion |
Aqueous injectable formulation |
| Hospital familiarity |
Established but narrower |
Broad |
| Generic pressure |
High |
High |
| Main advantage |
Fast adjustment and offset |
Availability, familiarity and cost |
| Main commercial weakness |
Cost and specialized formulation |
Longer offset and potential fluid considerations |
Clevidipine’s strongest defense is clinical workflow. Its weakest defense is economic substitution.
What patent litigation affects clevidipine?
No major current litigation event is established as a durable barrier to generic clevidipine entry in the public sources cited here. The primary legal risk is therefore ordinary ANDA litigation over any remaining listed formulation or use patents, rather than a broad patent dispute over the active molecule.
For investors and licensors, the relevant legal diligence points are:
- Current Orange Book patent listings
- ANDA approvals and tentative approvals
- Paragraph IV notices
- FDA litigation stays under Hatch-Waxman
- Settlement terms involving launch dates or licenses
- State and federal antitrust review of any reverse-payment agreement
Key Takeaways
- Clevidipine is a mature hospital injectable marketed in the U.S. as Cleviprex.
- Its value is concentrated in perioperative and critical-care blood-pressure control.
- The FDA approved Cleviprex in 2008, placing the product well beyond its initial regulatory exclusivity period.
- Chiesi acquired The Medicines Company’s cardiovascular franchise, including Cleviprex, in a transaction reported at approximately $792 million.
- Chiesi does not separately disclose current Cleviprex revenue, limiting product-level financial precision.
- Generic-entry risk is high because clevidipine is a small molecule with an established injectable presentation.
- The formulation creates manufacturing complexity but does not provide the same protection as active patent exclusivity.
- Nicardipine is the closest clinical competitor; labetalol, esmolol, nitroprusside and hydralazine expand hospital substitution risk.
- The likely financial trajectory is mature or declining revenue, with temporary upside possible from supply disruptions or hospital preference.
- Clevidipine is not a biologic, so biosimilar risk is not applicable.
FAQs
Is clevidipine a specialty pharmaceutical?
Clevidipine is a specialized hospital product rather than a specialty pharmacy medicine. It is administered intravenously in acute-care settings and is generally purchased through institutional channels.
Does clevidipine have biosimilar competition?
No. Clevidipine is a small-molecule drug. Competition proceeds through the ANDA generic-drug pathway, not the biosimilar pathway.
Can hospitals replace clevidipine with nicardipine?
Yes. Nicardipine is the closest therapeutic substitute, although the choice depends on the hospital protocol, patient characteristics, titration requirements and formulary economics.
Does Cleviprex have a durable manufacturing moat?
It has a technical manufacturing barrier because it is a sterile lipid emulsion. That barrier can reduce the number of qualified suppliers, but it is not equivalent to long-term patent exclusivity.
What would increase the commercial value of clevidipine?
A new approved use, persistent shortages of competing intravenous antihypertensives, strong clinical preference in a defined hospital segment or a limited generic supplier base could support value. None changes the product’s mature-market profile without new exclusivity or sustained demand expansion.
References
-
U.S. Food and Drug Administration. (2008). Cleviprex (clevidipine butyrate) injectable emulsion prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Chiesi Farmaceutici S.p.A. (2016). Chiesi Group acquires The Medicines Company’s cardiovascular portfolio in the United States. Chiesi Farmaceutici.
-
Chiesi Farmaceutici S.p.A. (2023). Annual report and financial statements. Chiesi Farmaceutici.
